Legorreta Pablo G. has filed 41 insider transactions across 2 companies since August 2022.
Most recent transaction: a grant/award of 157828 shares of Royalty Pharma plc ($RPRX) on February 11, 2026.
Activity breakdown: 7 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 11, 2026 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | A | Class A Ordinary Shares | 157828 | $0.00 | 4,703,158.0000 | 564,455,000 | 3.47% | 0.03% |
| Nov. 5, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | A | Class A Ordinary Shares | 36559 | $0.00 | 4,545,330.0000 | 566,754,000 | 0.81% | 0.01% |
| Aug. 6, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | A | Class A Ordinary Shares | 21901 | $0.00 | 4,508,771.0000 | 594,108,000 | 0.49% | 0.00% |
| Aug. 8, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | LP interests in RPI US Partners 2019, LP | 60000 | $0.00 | 6,379,566.0000 | 594,108,000 | 0.93% | 0.01% |
| June 3, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Class B Ordinary Shares | 3823996 | $0.00 | 84,283,430.0000 | 163,693,707 | 4.34% | 2.34% |
| June 3, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Class A Ordinary Shares | 3823996 | $0.00 | 26,441,905.0000 | 163,693,707 | 16.91% | 2.34% |
| June 3, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | J | Class A Ordinary Shares | 3823996 | $0.00 | 22,617,909.0000 | 163,693,707 | 14.46% | 2.34% |
| June 3, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Common Units in ProKidney LP | 3823996 | $0.00 | 84,283,430.0000 | 163,693,707 | 4.34% | 2.34% |
| May 29, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | A | Director stock option (right to buy) | 125862 | $0.00 | 125,862.0000 | 163,693,707 | 9999.99% | 0.08% |
| May 16, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | A | Class E Ordinary Shares | 13356742 | $0.00 | 13,356,742.0000 | 594,108,000 | 9999.99% | 2.25% |
| May 16, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | J | Class A Ordinary Shares | 530348 | $0.00 | 4,486,870.0000 | 594,108,000 | 13.40% | 0.09% |
| May 16, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | J | Option (Right to Buy) | 857138 | $0.00 | 857,138.0000 | 594,108,000 | 9999.99% | 0.14% |
| May 12, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | Class B Ordinary Shares | 867180 | $0.00 | 9,700,000.0000 | 594,108,000 | 9.82% | 0.15% |
| May 12, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | Class B Ordinary Shares | 867180 | $0.00 | 9,700,000.0000 | 594,108,000 | 8.21% | 0.15% |
| May 8, 2025 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | A | Class A Ordinary Shares | 288352 | $0.00 | 3,956,522.0000 | 594,108,000 | 7.86% | 0.05% |
| Feb. 4, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Class A Ordinary Shares | 532535 | $0.00 | 23,150,444.0000 | 163,693,707 | 2.35% | 0.33% |
| Feb. 4, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | J | Class A Ordinary Shares | 532535 | $0.00 | 22,617,909.0000 | 163,693,707 | 2.30% | 0.33% |
| Feb. 4, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Class B Ordinary Shares | 532535 | $0.00 | 88,107,426.0000 | 163,693,707 | 0.60% | 0.33% |
| Feb. 4, 2025 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Common Units in ProKidney LP | 532535 | $0.00 | 88,107,426.0000 | 163,693,707 | 0.60% | 0.33% |
| June 13, 2024 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | P | Class A Ordinary Shares | 22617909 | $2.42 | 22,617,909.0000 | 168,297,916 | 9999.99% | 13.44% |
| May 30, 2024 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | A | Director stock option (right to buy) | 62558 | $0.00 | 62,558.0000 | 168,297,916 | 9999.99% | 0.04% |
| Feb. 5, 2024 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | J | Class A Ordinary Shares | 748952 | $0.00 | 0.0000 | 168,297,916 | 100.00% | 0.45% |
| Feb. 5, 2024 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Class A Ordinary Shares | 748952 | $0.00 | 748,952.0000 | 168,297,916 | 9999.99% | 0.45% |
| Feb. 5, 2024 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Common Units in ProKidney LP | 748952 | $0.00 | 88,639,961.0000 | 168,297,916 | 0.84% | 0.45% |
| Feb. 5, 2024 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Not found | C | Class B Ordinary Shares | 748952 | $0.00 | 88,639,961.0000 | 168,297,916 | 0.84% | 0.45% |
| Nov. 16, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | J | Class A ordinary shares | 383000 | $0.00 | 3,668,170.4900 | 437,972,000 | 9.45% | 0.09% |
| Dec. 30, 2022 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | Class A ordinary shares | 292190 | $0.00 | 3,668,170.4900 | 0 | 8.65% | 0.00% |
| Oct. 30, 2023 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Director | J | Class A Ordinary Shares | 5289055 | $0.00 | 0.0000 | 171,578,320 | 100.00% | 3.08% |
| Oct. 30, 2023 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Director | C | Class A Ordinary Shares | 5289055 | $0.00 | 5,289,055.0000 | 171,578,320 | 9999.99% | 3.08% |
| Oct. 30, 2023 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Director | C | Common Units in ProKidney LP | 5289055 | $0.00 | 89,388,913.0000 | 171,578,320 | 5.59% | 3.08% |
| Oct. 30, 2023 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Director | C | Class B Ordinary Shares | 5289055 | $0.00 | 89,388,913.0000 | 171,578,320 | 5.59% | 3.08% |
| June 29, 2023 | PROKIDNEY CORP. | $PROK | Legorreta Pablo G. | Director | A | Director stock option (right to buy) | 48128 | $0.00 | 48,128.0000 | 171,578,320 | 9999.99% | 0.03% |
| June 28, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | P | Class A ordinary shares | 130000 | $29.51 | 3,758,980.0000 | 437,972,000 | 3.58% | 0.03% |
| June 12, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | P | Class A ordinary shares | 45000 | $33.00 | 3,583,980.0000 | 437,972,000 | 1.27% | 0.01% |
| June 13, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | P | Class A ordinary shares | 45000 | $32.78 | 3,628,980.0000 | 437,972,000 | 1.26% | 0.01% |
| May 24, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | P | Class A ordinary shares | 150000 | $32.25 | 3,538,980.0000 | 437,972,000 | 4.43% | 0.03% |
| May 17, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | P | Class A ordinary shares | 69612 | $32.94 | 3,388,980.0000 | 437,972,000 | 2.10% | 0.02% |
| May 16, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | P | Class A ordinary shares | 160388 | $33.57 | 3,319,368.0000 | 437,972,000 | 5.08% | 0.04% |
| May 12, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | ICAI Interests | 10269 | $0.00 | 1,700,189.0000 | 437,972,000 | 0.61% | 0.00% |
| May 12, 2023 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | ICAI Interests | 10269 | $0.00 | 1,700,189.0000 | 437,972,000 | 0.60% | 0.00% |
| Aug. 12, 2022 | Royalty Pharma plc | $RPRX | Legorreta Pablo G. | CEO, Chairman of the Board | G | LP interests in RPI US Partners 2019, LP | 150640 | $0.00 | 5,709,377.0000 | 0 | 2.57% | 0.00% |